Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCom.int.bk.regs Regulatory News (CBKD)

Share Price Information for Com.int.bk.regs (CBKD)

Share Price is delayed by 15 minutes
Get Live Data
2.415    -0.02 (-0.82%)
Bid:
2.415
Ask:
2.43
Spread: 0.015 (0.621%)
Market Cap: $7.97b
CBKD Live PriceLast checked at - London Stock Exchange

Intraday Com.int.bk.regs Share Chart

  • This share is an international stock.

CIB-Separate Financial Statements 3Q.2024

4 Nov 2024 07:00

RNS Number : 7504K
Commercial Intnl Bank (Egypt) SAE
03 November 2024
 

Condensed Separate Interim Statement of Financial Position as at September 30, 2024

Notes

Sep. 30, 2024

 

Dec. 31, 2023

 

 

Assets

 

 

 

Cash and balances at the central bank

9

94,285,689

 

71,747,343

Due from banks

10

304,041,116

 

230,709,419

Loans and advances to banks, net

12

3,323,215

 

822,448

Loans and advances to customers, net

13

301,909,242

 

233,824,745

Derivative financial instruments

1,769,619

 

1,101,896

Financial investments

 

 

 

- Financial Assets at Fair Value through P&L

14

2,066,889

 

-

- Financial Assets at Fair Value through OCI

14

222,440,208

 

232,290,598

- Financial Assets at Amortized cost

14

144,700,921

 

37,847,114

- Investments in subsidiaries and associates

15

871,525

 

671,525

Non current assets held for sale

28

159,828

 

159,828

Other assets

16

34,217,526

 

18,929,067

Deferred tax assets

1,870,814

 

1,685,223

Property and equipment

17

2,999,072

 

2,737,936

Total assets

 

1,114,655,664

 

832,527,142

Liabilities and equity

 

 

 

Liabilities

 

 

 

Due to banks

18

3,820,953

 

12,427,384

Due to customers

19

896,692,273

 

675,310,076

Derivative financial instruments

138,896

 

140,934

Current income tax liabilities

14,269,506

 

9,395,534

Other liabilities

20

21,685,718

 

18,307,580

Issued debt instruments

21

4,811,742

 

3,073,349

Other loans

20,324,693

 

12,483,907

Other provisions

22

15,471,381

 

11,088,372

Total liabilities

 

977,215,162

 

742,227,136

Equity

 

 

 

Issued and paid up capital

30,431,580

 

30,195,010

Reserves

61,951,798

 

29,388,626

Reserve for employee stock ownership plan (ESOP)

1,667,230

 

1,486,010

Retained earnings *

43,389,894

 

29,230,360

Total equity and net profit for the period / year

 

137,440,502

 

90,300,006

Total liabilities and equity

 

1,114,655,664

 

832,527,142

The accompanying notes are an integral part of these financial statements.

 

( Limited Review report attached )

 

*

Including net profit for the period

 

 

 

Condensed Separate Interim Income Statement for the period ended September 30, 2024

 

 

Last 9 Months

 

Last 9 Months

 

Notes

Sep. 30, 2024

 

Sep. 30, 2023

 

 

 

 

 

 

 

Interest and similar income

130,537,149

 

72,741,395

 

Interest and similar expense

(65,010,779)

 

(35,154,201)

 

Net interest income

 

65,526,370

 

37,587,194

 

 

 

 

Fee and commission income

9,257,495

 

6,540,630

 

Fee and commission expense

(4,048,928)

 

(2,590,207)

 

Net fee and commission income

 

5,208,567

 

3,950,423

 

 

 

 

Dividend income

100,858

 

100,244

 

Net trading income

6

18,177,630

 

3,146,544

 

Profits (Losses) on financial investments 

14.1

377,992

 

(1,256,233)

 

Administrative expenses

(8,795,429)

 

(6,304,022)

 

Other operating income (expenses)

7

(17,980,232)

 

(5,293,795)

 

Impairment release (charges) for credit losses

(3,741,208)

 

(1,248,897)

 

Profit before income tax

 

58,874,548

 

30,681,458

 

 

 

 

Income tax expense

26

(16,964,163)

 

(9,540,541)

 

Deferred tax assets (Liabilities)

26

646,991

 

591,159

 

Net profit for the period

 

42,557,376

 

21,732,076

 

 

 

 

Earnings per share

8

 

 

 

Basic

12.42

 

6.41

 

Diluted

12.26

 

6.33

 

 

 

 

 

 

Islam Zekry

 

Hisham Ezz Al-Arab

 

Group CFO

 

Chairman

 

 

 

 

 

 

 

Condensed Separate Interim Statement of Comprehensive Income for the period ended September 30, 2024

 

Last 9 Months

 

Last 9 Months

Sep. 30, 2024

 

Sep. 30, 2023

 

 

 

 

Net profit for the period

 

42,557,376

 

21,732,076

 

 

Change in fair value of Financial invesments measured at fair value through comprehensive income after tax

8,284,110

 

(9,611,703)

Transferred to RE from financial assets at fair value through comprehensive income

(370,224)

 

(95,308)

Effect of ECL on fair value of debt instruments measured at fair value through comprehensive income

624,524

 

197,888

Total comprehensive income for the period

 

51,095,786

 

12,222,953

 

 

 

Condensed Separate Interim Cash Flows for the period ended September 30, 2024

 

Notes

Sep. 30, 2024

 

Sep. 30, 2023

 

 

Cash flow from operating activities

 

 

 

Profit before income tax

58,874,548

 

30,681,458

Adjustments to reconcile profits to net cash provided by operating activities

 

 

 

Fixed assets depreciation

17

763,079

636,285

Impairment Release/charge for credit losses (Loans and advances to customers and banks)

4,226,051

1,088,174

Other provisions Release/charge

22

429,182

2,350,347

Impairment Release/charge for credit losses (due from banks)

(5)

(49,019)

Impairment Release/charge for credit losses (financial investments)

(484,838)

209,742

Impairment Release/charge for other assets

(11,956)

14,347

Exchange revaluation differences for financial assets at fair value through OCI and AC

(18,536,183)

(5,409,592)

Revaluation differences Impairment charge for Financial Assets at Fair value through OCI

1,199,896

-

Revaluation differences Impairment charge for Financial Assets at Amortized cost

107,207

-

Revaluation differences Impairment charge for due from banks

107

-

Utilization of other provisions

22

(9,196)

(1,608)

Exchange revaluation differences of other provisions

22

3,963,023

1,096,665

Profits/losses from selling property and equipment

(2,254)

(194)

Profits/losses from selling financial investments at fair value through OCI

14.1

(377,992)

(149,012)

Losses (Profits) from selling investments in associates

14.1

-

(7,466)

Share based payments

804,345

608,250

Impairment Release/charges of investments in associates and subsidiaries

14.1

-

1,412,711

Operating profits before changes in operating assets and liabilities

 

50,945,014

 

32,481,088

 

 

Net decrease / increase in assets and liabilities

 

 

 

Due from banks

(24,748,544)

5,142,259

Financial assets at fair value through P&L

(2,066,889)

-

Derivative financial instruments

(229,127)

172,635

Loans and advances to banks and customers

12-13

(74,803,105)

(27,805,660)

Other assets

(14,036,648)

(2,507,984)

Due to banks

18

(8,606,431)

15,554,567

Due to customers

19

221,382,197

135,770,021

Current income tax obligations paid

(2,694,657)

(2,547,087)

Other liabilities

(6,305,033)

874,366

Net cash generated from (used in) operating activities

 

138,836,777

 

157,134,205

 

 

Cash flow from investing activities

 

 

 

Proceeds from sale of investments in associates

11,956

2,119

Payments for investment in subsidiaries

(200,000)

(1,216,022)

Payments for purchases of property, equipment and branches construction

(2,284,236)

(1,162,819)

Proceeds from selling property and equipment

2,254

194

Proceeds from redemption of financial assets at amortized cost

1,093,724

5,278,030

Payments for purchases of financial assets at amortized cost

(105,723,312)

(9,178,811)

Payments for purchases of financial assets at fair value through OCI

(21,646,713)

(65,109,765)

Proceeds from selling financial assets at fair value through OCI

67,015,091

76,347,190

Net cash generated from (used in) investing activities

 

(61,731,236)

4,960,116

Condensed Separate Interim Cash Flows for the period ended September 30, 2024 (Cont.)

 

Sep. 30, 2024

 

Sep. 30, 2023

 

 

Cash flow from financing activities

 

 

 

Other loans

7,840,786

2,408,739

Dividends paid

(5,078,792)

(3,738,888)

Issued debt instruments

1,738,393

615,227

Capital increase

236,570

369,876

Net cash generated from (used in) financing activities

 

4,736,957

(345,046)

 

 

Net (decrease) increase in cash and cash equivalent during the period

81,842,498

161,749,275

Beginning balance of cash and cash equivalent

233,912,193

 

92,895,143

Cash and cash equivalent at the end of the period

 

315,754,691

 

254,644,418

 

 

Cash and cash equivalent comprise:

 

 

 

Cash and balances at the central bank

9

94,285,689

 

59,818,535

Due from banks

304,041,410

 

276,244,266

Treasury bills and other governmental notes

11

82,174,775

71,507,826

Obligatory reserve balance with CBE

(76,128,521)

 

(52,853,882)

Due from banks with maturity more than three months

(17,846,556)

(29,659,932)

Treasury bills and other governmental notes with maturity more than three months

(70,772,106)

(70,412,395)

Total cash and cash equivalent

 

315,754,691

 

254,644,418

 

 

Condensed Separate Interim statement of changes in shareholders' equity

 

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Sep. 30, 2023

Beginning Balance at 1 January 2023

29,825,134

3,963,946

27,096,858

1,549,445

18,947

(13,138,461)

11,981

16,497,346

1,895,435

67,720,631

Capital increase

369,876

-

-

-

-

-

-

-

-

369,876

Transferred to reserves

-

806,408

12,743,849

-

2,208

-

-

(12,388,223)

(1,164,242)

-

Dividend paid

-

-

-

-

-

-

-

(3,738,888)

-

(3,738,888)

Net profit for the period

-

-

-

-

-

-

-

21,732,076

-

21,732,076

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

(95,308)

-

95,308

-

-

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

(9,611,703)

-

-

-

(9,611,703)

Transferred (from) to bank risk reserve

-

-

-

-

-

-

3,249

(3,249)

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

197,888

-

-

-

197,888

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

608,250

608,250

Balance at 30 September 2023

30,195,010

4,770,354

39,840,707

1,549,445

21,155

(22,647,584)

15,230

22,194,370

1,339,443

77,278,130

Sep. 30, 2024

 

 

 

 

 

 

 

 

 

 

Beginning Balance at 1 January 2024

30,195,010

4,770,354

39,840,707

1,549,445

21,155

(16,808,265)

15,230

29,230,360

1,486,010

90,300,006

Capital increase

236,570

-

-

-

-

-

-

-

-

236,570

Transferred to reserves

-

1,438,320

22,582,085

-

1,663

-

-

(23,398,943)

(623,125)

-

Dividend paid

-

-

-

-

-

-

-

(5,366,429)

-

(5,366,429)

Net profit for the period

-

-

-

-

-

-

-

42,557,376

-

42,557,376

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

(370,224)

-

370,224

-

-

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

8,284,110

-

-

-

8,284,110

Transferred (from) to banking risk reserve

-

-

-

-

-

-

2,694

(2,694)

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

624,524

-

-

-

624,524

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

804,345

804,345

 Balance at 30 September 2024

30,431,580

6,208,674

62,422,792

1,549,445

22,818

(8,269,855)

17,924

43,389,894

1,667,230

137,440,502

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTBJBPTMTMMBJI
Date   Source Headline
12th May 202610:18 amRNS1st Quarter Results
12th May 202610:16 amRNSCIB Consolidated Financial Statements 1Q26
12th May 202610:15 amRNS1Q26 Earnings Release
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
24th Feb 202612:31 pmRNSItems of Extraordinary GA
24th Feb 20267:00 amRNSPress Release dated 23th February 2026
19th Feb 20261:20 pmRNSItems of Extraordinary GA
19th Feb 20261:17 pmRNSInvitation to the Extraordinary GA 2026
19th Feb 20268:00 amRNSItems of OGA 2026
19th Feb 20268:00 amRNSInvitation to the OGA March 15
10th Feb 20267:00 amRNSCIB Summary of Board Resolution 9 Feb 2026
10th Feb 20267:00 amRNSFY25 Earnings Release
10th Feb 20267:00 amRNSCIB IFRS Consolidated Financial Statements FY25
15th Dec 20257:00 amRNSChange in Board of Directors
3rd Dec 20254:35 pmRNSCIB Bonus Shares Distribution 2025
4th Nov 20257:00 amRNSCIB Condensed Consolidated 3rd Quarter Results
4th Nov 20257:00 amRNSCIB 9M25 Earnings Release
4th Nov 20257:00 amRNS3rd Quarter Results
25th Sep 20253:55 pmRNSSummary of Resolutions - GAM September 2025
1st Sep 20257:02 amRNSInvitation to General Assembly September 2025
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Consolidated Financials
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Separate Financials
22nd Jul 20257:00 amRNS2Q25 Earnings Release
28th May 20256:00 pmRNSChanges to the Board of Directors
13th May 20257:00 amRNSSeparate- Q12025
13th May 20257:00 amRNS1Q25 Press Release
13th May 20257:00 amRNSConsolidated Financial Position at March 31.2025
24th Mar 20257:00 amRNSOrdinary General Assembly Resolutions Summary 2025
28th Feb 20257:00 amRNSGeneral Assembly 2025 - Discussion Items - amended
27th Feb 20257:47 amRNSInvitation to General Assembly 2025
27th Feb 20257:15 amRNSGeneral Assembly 2025 - Discussion Items
19th Feb 20257:00 amRNSCIB Annual Financial Report
19th Feb 20257:00 amRNSCIB FY2024 Earnings Release
6th Nov 20247:58 amRNSCIB gets regulatory approvals to changes to BoD
4th Nov 20247:00 amRNSEarnings Release 3Q.2024
4th Nov 20247:00 amRNSCIB-Separate Financial Statements 3Q.2024
4th Nov 20247:00 amRNSCIB-Consolidated Financial Statements 3Q.2024
1st Oct 20242:00 pmRNSCIB obtaining Long term loan from IFC
16th Sep 20248:00 amRNSChanges in CIB's Board of Directors
22nd Jul 20247:00 amRNSH1.2024 Press Release
22nd Jul 20247:00 amRNSCIB H1-2024 Separate Financial Statements - E
22nd Jul 20247:00 amRNSCIB H1-2024 Consolidated Financial Statements
13th May 20247:00 amRNS1st Quarter Results - Consolidated Statements
13th May 20247:00 amRNS1st Quarter Results - Separate Statements
26th Mar 20247:49 amRNSChanges in CIB's BOD - 25 March 2024
26th Mar 20247:00 amRNSEGM Resolutions - March 25th, 2024
26th Mar 20247:00 amRNSOGM Resolutions - March 25th, 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.